paediatric oncology

Oncology

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

News

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.